Drugs that contain Netarsudil Mesylate
1. Rhopressa patents expiration
RHOPRESSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9096569 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US8450344 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US10174017 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US10654844 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US8394826 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(6 years from now) | |
| US10588901 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(10 years from now) | |
| US9931336 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(10 years from now) | |
| US9415043 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021456 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US10532993 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US10882840 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US11618748 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US11028081 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US11185538 | AERIE PHARMS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2022 |
NCE-1 date: 2021-12-18
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of RHOPRESSA before it's drug patent expiration?
More Information on Dosage
RHOPRESSA family patents
